NorthWest Biotherapeutics Inc (NWBO)

[newman2021]

Yes. First of all an mOS is not a good indicator at all in expressing the efficacy of immunotherapy drugs. The world is used to capture the median values in an abstract of an R&D article and the same dame approach is no good in immunotherapy papers in my humble opinion. The abstract should rather list one yr, 2 yr, 3 yr %of patients alive in treatment vs placebo or standard therapy ..... that should be the norm hereafter so that the fudsters like Ex can be stopped in their attempt to confuse the commons.